Kling Biotherapeutics to Present Key Applications for its Primary B-Cell Immortalization, Screening and Antibody Optimization Platform Technologies at PEGS Europe

Kling Biotherapeutics Netherlands

Kling-Select is a uniquely promising approach to identifying novel targets and therapeutic antibodies from human and animal sourcesKling-Evolve enables highly rapid selection of effective neutralizing antibodies against viral escape variantsView original content:https://www.prnewswire.co.uk/news-releases/kling-biotherapeutics-to-present-key-applications-for-its-primary-b-cell-immortalization-screening-and-antibody-optimization-platform-technologies-at-pegs-europe-302292023.html